Covance appoints Merck's Raymond Kaiser
This article was originally published in Scrip
Drug development services company Covance has appointed Dr Raymond Kaiser global science leader and vice-president for biotechnology services, replacing Dr Carl Martin who will retire from this role after 35 years at Covance. Dr Kaiser joins the company from Merck Research Laboratories where he was executive director of bioprocess research and development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.